Low-dose doxorubicin plus peposertib for advanced sarcoma
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sarcoma confirmed by pathology, and it is advanced (metastatic or not operable) with no curative option
- Your sarcoma type is leiomyosarcoma or one of these: myxofibrosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, or dedifferentiated liposarcoma
- Your cancer has at least one area that can be checked by biopsy (biopsy must be possible)
- You are 18 or older and you have had at least one prior cancer treatment line
- Your body can handle treatment based on blood counts and organ tests (blood counts, liver, kidney) and you’re generally able to do daily activities (ECOG 0–2)
- You can safely take study medicines: you must be able to swallow tablets, not have active brain/spread to the brain that’s progressing, and you must not have had prior treatment with a DNA-PK inhibitor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
This trial is testing a new treatment for advanced dedifferentiated liposarcoma that has not been treated yet. The goal is to see if the treatment can help shrink or slow the cancer.
This trial tests whether adding a new drug called DT-7012 to standard chemotherapy (doxorubicin) works better than chemotherapy alone for two types of advanced soft tissue sarcoma. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Hear when a new Metastatic Dedifferentiated Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.